NASHVILLE, Tenn. / Nov 15, 2024 / Business Wire / Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences:
Craig-Hallum 15th Annual Alpha Select Conference (Sheraton New York Times Square Hotel)
November 19, 2024
1x1 Meetings Only
BTIG 4th Annual Ophthalmology Day (Virtual)
December 2, 2024
1x1 Virtual Meetings Only
Piper Sandler 36th Annual Healthcare Conference (The Lotte New York Palace)
December 3-5, 2024
Company will host a Fireside Chat at 8:00 a.m. ET on December 4, 2024
The Company will conduct one-on-one meetings at each conference. Investors interested in meeting with management during conferences should contact their representative at each firm to request a meeting. Only the Piper Sandler conference will include an audio webcast, which will be available on the Company’s website.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
Last Trade: | US$42.13 |
Daily Change: | 2.12 5.30 |
Daily Volume: | 553,974 |
Market Cap: | US$1.560B |
October 06, 2025 September 26, 2025 September 08, 2025 August 11, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load